FDA Approves Eliquis® to Prevent DVT After Hip and Knee Replacements

The anticoagulant Eliquis® has been approved by FDA to prevent prophylaxis of deep vein thrombosis (DVT) after hip or knee replacement surgery.  DVT is a serious medical condition that may lead to pulmonary embolism.  Eliquis®  was previously approved to reduce the risk of stroke in patients with non-vavlular atrial fibrillation

[1] FDA NDA 202155/S-003 (March 13, 2014).
[2] FDA News Release "FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation," (December 28, 2012).

---